116 filings
Page 4 of 6
8-K
nw387hk
23 Jan 23
TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors
7:06am
UPLOAD
v8laoa8bjlrrof5818t
15 Nov 22
Letter from SEC
12:00am
UPLOAD
6rvuq p8cnq8b8
15 Nov 22
Letter from SEC
12:00am
S-3
c80vz0lw6nsn7fo
9 Nov 22
Shelf registration
7:53am
8-K
p89mg85
9 Nov 22
TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
7:06am
8-K
l3a05
12 Sep 22
TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures
7:51am
8-K
720pnivzsk4h6xlqqtv
10 Aug 22
TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
12:00am
8-K
dbnjghbmvzo160sr
7 Jul 22
Departure of Directors or Certain Officers
7:11am
8-K
fjq0a58l
3 Jun 22
Departure of Directors or Certain Officers
4:03pm
8-K
7ho4g ea07
31 May 22
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies
7:07am
8-K
a8lrocqdvzxkfw0ua4uz
9 May 22
TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones
7:08am
DEFA14A
k5ta1xp
21 Apr 22
Additional proxy soliciting materials
8:05am
DEF 14A
bcy5a8v430or4jpi00x8
21 Apr 22
Definitive proxy
8:00am
S-8
zbgctf0sim3bm6
9 Mar 22
Registration of securities for employees
7:46am
10-K
i5x2k
9 Mar 22
Annual report
7:30am
8-K
gyef5
9 Mar 22
TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities
7:13am